Innavasc
Durham, US · Founded 2013 · 2 known investors
InnAVasc develops a vascular access graft for hemodialysis, featuring self-sealing pods and puncture-resistant backplates that guide dialysis needle placement to reduce needle-injury and bleeding complications. The product targets patients requiring hemodialysis access.
BiotechHardwareHealthtechMedical Devices
Founders & leadership
SG
Shawn GageExecutive Officer
DB
Dani BolognesiDirector
JL
Jeffrey LawsonExecutive Officer, Director
JK
Joseph KnightExecutive Officer, Director
RD
Roberto Duane MansonExecutive Officer
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$1MraisedNov 2021 · 41 investors · BiotechnologyRule 506(b)
▶$1MraisedNov 2021 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- C. Steven DunckerDirector
- Craig NicholsExecutive Officer
- William N, StarlingDirector
- Greg DavisDirector
- Joseph KnightExecutive Officer, Director
- Kenneth GallDirector
- Jeffrey LawsonDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Nov 2021
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$414.5KraisedApr 2020 · 20 investors · BiotechnologyRule 506(b)
▶$414.5KraisedApr 2020 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- C Steven DunckerDirector
- William N StarlingDirector
- Greg DavisDirector
- Kenneth GallDirector
- Joseph KnightExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $414.5K
- First sale
- Apr 2020
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$500KraisedOct 2018 · 17 investors · BiotechnologyRule 506(b)
▶$500KraisedOct 2018 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Greg DavisDirector
- William Starling,Jr.Director
- Craig NicholsExecutive Officer
- Stephen DunckerDirector
- Kenneth GallDirector
- Joseph KnightExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $500K
- First sale
- Oct 2018
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$2.1MraisedNov 2016 · 39 investors · BiotechnologyRule 506(b)
▶$2.1MraisedNov 2016 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn GageExecutive Officer
- Dani BolognesiDirector
- Jeffrey LawsonExecutive Officer, Director
- Joseph KnightExecutive Officer, Director
- Roberto Duane MansonExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $2.1M
- First sale
- Oct 2016
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
▶$520KraisedApr 2016 · 14 investors · BiotechnologyRule 506(b)
▶$520KraisedApr 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey LawsonExecutive Officer, Director
- Joseph KnightExecutive Officer, Director
- Roberto MansonExecutive Officer
- Shawn GageExecutive Officer
- Dani BolognesiDirector
- Offering amount
- $1M
- Amount sold
- $520K
- First sale
- Apr 2016
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Science Foundation | Phase II | 2020 | $749.9K |
| National Science Foundation | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.